Targeted therapy for ovarian cancer: the rapidly evolving landscape of PARP inhibitor use.

CONCLUSIONS: The landscape of PARP inhibitor use for ovarian cancer is rapidly evolving and PARP inhibitors have become more available as a targeted therapy option for ovarian cancer treatment. PMID: 28994564 [PubMed - as supplied by publisher]
Source: Minerva Ginecologica - Category: OBGYN Tags: Minerva Ginecol Source Type: research